RepliCel has completed phase 1 human clinical studies in androgenetic alopecia, aging & sun-damaged skin, and chronic Achilles tendinopathy.
The only study currently underway is a clinical study investigating RCH-01 for androgenetic alopecia in Japan. This is being managed and funded by Shiseido and is open only to Japanese citizens.
We are now moving as quickly as possible to next phase clinical studies in dermatology, tendon, and hair (anticipated to be likely in that order). If you are interested in signing up to stay informed or to register your interest in participating in a future trial (should one be located in your area), please visit the related product's study page.